Allergan closes $800 million amended revolver, extends to 2016

By Aleesia Forni

Columbus, Ohio, Oct. 31 - Allergan, Inc. entered into an $800 million amended and restated revolving credit facility, according to an 8-K filed with the Securities and Exchange Commission.

Pricing on the facility is based on the company's credit rating and ranges from Libor plus 45 basis points to 117.5 bps.

Facility fees range from 5 bps to 20 bps.

The facility is set to mature on October 2016.

Allergan's eligible subsidiaries may borrow up to $250 million under this agreement.

Under the amended facility, Allergan may obtain committed loans or competitive bid loans.

Both may be funded in U.S. dollars, euros, Canadian dollars, Japanese yen, pounds and Australian dollars.

The amended agreement also contains a $100 million subfacility for letters of credit and a $50 million swingline subfacility.

J.P. Morgan Securities LLC and Citigroup Global Markets, Inc. are joint lead arrangers and joint bookrunners.

JPMorgan Chase Bank NA is administrative agent, while Citibank NA is syndication agent.

Bank of America NA is documentation agent.

Allergan is an Irvine, Calif.-based multi-specialty health care company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.